🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT07129551
Recruiting Not applicable

Navigation, Outcomes and Quality-of-life in Prostate Cancer Patients Undergoing PSMA-targeted Surgery

NCT07129551 · tracked via the Priya Life Science Germany tracker
Phase
Not applicable
Started
2026-01-21
Last updated
2026-01-12

Condition(s) studied

Prostate Cancer (Adenocarcinoma)

Investigational drug(s) / intervention(s)

preop virtual 3D modelpostop 3D model

preop virtual 3D model: Cohort A: Radical prostatectomy with PSMA-targeted lymph node dissection (separate specimen) and bilateral extended pelvic lymph node dissection with additional use of a virtual 3D-model (of preoperative PSMA-PET examination) prior to surgery and postoperatively; Cohort B: Salvage lymph node dissection with PSMA-targeted lymph node dissection (separate specimen) and at least ipsilateral pelvic template lymph node dissection with additional use of a virtual 3D-model (of preoperative PSMA-PET examination) prior to surgery and postoperatively

postop 3D model: Cohort A: Radical prostatectomy with PSMA-targeted lymph node dissection (separate specimen) and bilateral extended pelvic lymph node dissection with use of standard PSMA-PET examination prior to surgery; only postoperatively a virtual 3D-model (of preoperative PSMA-PET examination) will be evaluated; Cohort B: Salvage lymph node dissection with PSMA-targeted lymph node dissection (separate specimen) and at least ipsilateral pelvic template lymph node dissection with use of standard PSMA-PET examination prior to surgery; only postoperatively a virtual 3D-model (of preoperative PSMA-PET examination) will be evaluated

Study summary

As part of a feasibility study, it's planned to use a 3D virtual mixed reality model with prostate cancer patients who show signs of lymph node metastasis and are scheduled for surgery. The model is based on PSMA PET imaging performed prior to surgery and will be evaluated by surgeons, the surgical team, and patients as part of the consultation process. First, the researcher investigates whether the removal of lymph node metastases has improved compared to the data in the literature . In addition, the study examines how the 3D model influences the movement of surgical instruments and the efficiency of surgical removal of lymph node metastases. To this end, the analyzed recorded video and position data of the instruments used during procedures performed with a surgical robot. It's also an aim to develop two methods-using landmarks and visual position tracking-for more targeted navigation during surgery. Additionally, short-term results examine, such as PSA response rates, as an indication of successful lymph node metastasis removal and patient quality of life.

Eligibility

Sex
MALE
Min age
18 Years
Max age
78 Years
Healthy volunteers
No
Inclusion Criteria: Cohort A: * Patients with hormone-sensitive prostate cancer scheduled for radical prostatectomy with pelvic lymph node dissection * \<3 PSMA-PET-avid lymph node metastases (PSMA expression score \>2) in the pelvis. Cohort B: * Patients with hormone-sensitive recurrent prostate cancer after radical prostatectomy with planned pelvic salvage lymph node dissection * \<3 PSMA-PET-avid lymph node metastases (PSMA expression score \>2) in the pelvis * PSA value \<2ng/ml. Exclusion Criteria: * Estimated life expectancy \<10 years * contraindication for surgical intervention * androgen deprivation therapy (ADT) within the last 3 months

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Martini-Klinik Hamburg Free and Hanseatic City of Hamburg Recruiting
Anke Renter Hamburg Free and Hanseatic City of Hamburg Not Yet Recruiting

More Martini-Klinik am UKE GmbH trials in Germany

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07129551 on ClinicalTrials.gov ↗ ← All trials in Germany